Alterity Therapeutics (ATHE) Return on Capital Employed (2009 - 2024)
Alterity Therapeutics (ATHE) posted quarterly Return on Capital Employed of 189.02% for Q2 2024, up 9431.0% year-over-year from 1.98% in Q3 2023, and up 33.29% quarter-over-quarter from 283.33% in Q2 2023.
Alterity Therapeutics (ATHE) Return on Capital Employed (2009 - 2024) Analysis & Trends
Alterity Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 189.02% for Q2 2024.
- In Q2 2024, Return on Capital Employed rose 9431.0% year-over-year to 189.02%; the TTM figure through Jun 2024 stood at 189.02% (up 9431.0% YoY), while the FY2023 annual figure was 43.99%, down 414.0% from the prior year.
- Return on Capital Employed for Q2 2024 stood at 189.02%, up from 283.33% in the prior quarter.
- The five-year high for Return on Capital Employed was 95.63% in Q2 2022, with the low at 283.33% in Q2 2023.
- The 3-year median for Return on Capital Employed is 189.02% (2024), against an average of 189.33%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 18770 bps in 2023, then soared 9431 bps in 2024.
- Alterity Therapeutics' Return on Capital Employed stood at 95.63% in 2022, then sank by 196 bps to 283.33% in 2023, then soared by 33 bps to 189.02% in 2024.
- Business Quant data shows ATHE's Return on Capital Employed at 189.02% in Q2 2024, 283.33% in Q2 2023, and 95.63% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 7.88% |
| 10 | Alterity Therapeutics | 49.04 Mn | 16.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -189.02% |
| Jun 30, 2023 | -283.33% |
| Jun 30, 2022 | -95.63% |
| Dec 31, 2019 | -235.76% |
| Jun 30, 2019 | -0.43% |
| Dec 31, 2018 | -0.36% |
| Jun 30, 2018 | -127.83% |
| Dec 31, 2017 | -0.16% |
| Jun 30, 2017 | -0.19% |
| Dec 31, 2016 | -0.20% |
| Jun 30, 2010 | -535.76% |
| Jun 30, 2009 | -509.07% |